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The protocadherin 17 gene affects cognition, personality,
amygdala structure and function, synapse development and
risk of major mood disorders
H Chang1,33, N Hoshina2,3,33, C Zhang4,33, Y Ma5, H Cao6, Y Wang7, D-d Wu7, SE Bergen8,9, M Landén8,10, CM Hultman8, M Preisig11,
Z Kutalik12,13, E Castelao11, M Grigoroiu-Serbanescu14, AJ Forstner15,16, J Strohmaier17, J Hecker15,18, TG Schulze19,
B Müller-Myhsok20,21,22, A Reif23, PB Mitchell24,25, NG Martin26, PR Schofield27,28, S Cichon15,16,29,30, MM Nöthen15,16, The Swedish
Bipolar Study Group34, MooDS Bipolar Consortium34, H Walter31, S Erk31, A Heinz31, N Amin32, CM van Duijn32, A Meyer-Lindenberg6,
H Tost6, X Xiao1, T Yamamoto2,35, M Rietschel17,35 and M Li1,35
Major mood disorders, which primarily include bipolar disorder and major depressive disorder, are the leading cause of disability
worldwide and pose a major challenge in identifying robust risk genes. Here, we present data from independent large-scale clinical
data sets (including 29 557 cases and 32 056 controls) revealing brain expressed protocadherin 17 (PCDH17) as a susceptibility gene
for major mood disorders. Single-nucleotide polymorphisms (SNPs) spanning the PCDH17 region are significantly associated with
major mood disorders; subjects carrying the risk allele showed impaired cognitive abilities, increased vulnerable personality
features, decreased amygdala volume and altered amygdala function as compared with non-carriers. The risk allele predicted
higher transcriptional levels of PCDH17 mRNA in postmortem brain samples, which is consistent with increased gene expression in
patients with bipolar disorder compared with healthy subjects. Further, overexpression of PCDH17 in primary cortical neurons
revealed significantly decreased spine density and abnormal dendritic morphology compared with control groups, which again is
consistent with the clinical observations of reduced numbers of dendritic spines in the brains of patients with major mood
disorders. Given that synaptic spines are dynamic structures which regulate neuronal plasticity and have crucial roles in myriad
brain functions, this study reveals a potential underlying biological mechanism of a novel risk gene for major mood disorders
involved in synaptic function and related intermediate phenotypes.
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INTRODUCTION
A major challenge in modern medicine is to understand the
molecular and cellular mechanisms underlying common mental
illnesses such as the major mood disorders, which primarily
include bipolar disorder (BPD) and major depressive disorder
(MDD) with a combined lifetime prevalence of up to 20% and a
leading cause of morbidity worldwide.1 Clinical, epidemiological
and genetic findings have suggested shared risk factors between
BPD and MDD.2 Despite considerable evidence of heritability,2
the neurobiology of major mood disorders remains poorly
understood due to the lack of biomarkers, phenotypic
uncertainties, and heterogeneity of precipitating factors. However,
accumulating basic and clinical studies point to aberrant
structures and dysfunction of brain regions that engage in
emotional and cognitive processes, such as prefrontal cortex,
hippocampus and amygdala. Dysregulated neuronal synapses
in these brain areas,3,4 and the effect of antidepressive medica-
tion on these brain regions5 also suggest their involvement
in the neurobiological mechanism of major mood disorders.
Therefore, gene identification for complex diseases such as major
mood disorders will require demonstration that risk variants
affect the key aspects of the biology of the illness.6 Indeed, this
logic has proven to be crucial in a number of complex disorders,
such as adult onset diabetes, in which multiple genes each
account for only a very small share of genetic risk, but show
stronger effects on related intermediate phenotypes even in
healthy individuals, such as body mass index7 or glucose-induced
insulin release.8
To date, genome-wide association studies (GWAS) have been
conducted in several mood disorder samples, identifying several
genome-wide significant genes (either across disorders or for
single illness), such as ANK3, CACNA1C, ODZ4, NCAN, PBRM1 and
TRANK1.9–15 It has been increasingly recognized that major mood
disorders are polygenic, with numerous alleles each accounting
for a very small share of genetic risk in the illness.16 Those
genome-wide significant genes only explain a small portion of the
genetic liability and the sources of missing heritability are still
unclear. GWAS is an effective tool to discover the novel risk genes
with strong effects, as it entails scanning the genome with
hundreds of thousands of genetic variations and employing rigid
statistical correction to avoid false positives. This strategy has been
successful for several complex disorders with very large samples,
such as schizophrenia,17 type 2 diabetes18 and blood pressure.19
However, when the sample sizes are inadequate, the stringent
corrections of GWAS preclude the ability to discover genuine risk
genes that are of substantial biological interest in spite of only
reaching nominal significance. Alternatively, at present, other
approaches such as convergent functional genomics,20 gene
expression profiling,21 or candidate gene studies with a priori
hypotheses22 are still necessary to identify potential susceptibility
genes for major mood disorders.
The cell adhesion proteins, protocadherins, through their effects
on guiding neurons during development, neuronal differentiation
and synaptogenesis,23 are feasible targets in the pathogenesis of
major mood disorders. Among those protocadherin family
members, PCDH17 (protocadherin 17) is expressed by a subset
of amygdala neurons,24 and PCDH17 knockout mice exhibit
antidepressant–like phenotypes,25 implying potential involvement
of PCDH17 in major mood disorders. Notably, a previous linkage
study on mood–incongruent psychotic features showed strong
evidence for linkage on human chromosome 13q21-33,26 the
genomic region where PCDH17 gene was located (13q21.1). These
convergent lines of evidence suggest PCDH17 is a plausible
susceptibility gene for major mood disorders, but direct evidence
of association is still absent.
Here, we conduct a meta-analysis of independent clinical
samples including a total of 29 557 cases and 32 056 controls and
we report a novel risk candidate gene PCDH17 for major mood
disorders. Single-nucleotide polymorphisms (SNPs) spanning the
PCDH17 region were found to be associated with mood disorders
across multiple independent samples. We describe its association
with several biological intermediate phenotypes such as cogni-
tion, emotion, and amygdala structures and functions. We show
that the risk alleles predict higher PCDH17 mRNA levels in
postmortem brains, consistent with its increased expression in
patients compared with healthy controls. Elevated expression of
PCDH17 in primary neuronal cultures revealed decreased spine
density and aberrant dendritic morphology. Such changes in
dendritic spines may underlie abnormalities in synaptic function
thought to be a fundamental aspect of brain dysfunction in major
mood disorders. These convergent results implicate PCDH17 in the
biology of synapses and in the etiology and pathophysiology of
major mood disorders, making it a potential new target for the
pharmacotherapy of these conditions.
MATERIALS AND METHODS
All the protocols and methods used in this study were approved by the
institutional review board of the Kunming Institute of Zoology, Chinese
Academy of Sciences and adhere to all relevant national and international
regulations.
Clinical association samples
In the discovery stage, we performed a meta-analysis using statistics from
a BPD GWAS which has been described in Ruderfer et al.27 and a non-
overlapped MDD GWAS which has been described elsewhere.28 In brief,
the BPD GWAS sample included 10 410 cases and 10 700 controls, it has
partial overlap with the Psychiatric Genomics Consortium (PGC) BPD
GWAS,12 but also includes four additional BPD samples compared with the
PGC GWAS.12 Standardized semi-structured interviews were used to collect
clinical information about lifetime history of psychiatric illness, and
operational criteria were applied to make lifetime diagnoses. All cases
have experienced pathologically relevant episodes of elevated mood
(mania or hypomania) and meet the criteria for BPD within the primary
study classification system. Controls were selected from the same
geographical and ethnic populations as the cases and had a low
probability of having BPD.
The MDD GWAS includes 9227 patients and 7383 controls. Cases were
required to have diagnoses of DSM-IV lifetime MDD established using
structured diagnostic instruments from direct interviews by trained
interviewers or clinician-administered DSM-IV checklists. Most samples
ascertained cases from clinical sources, and most controls were randomly
selected from the population and screened for lifetime history of MDD. In
each GWAS, logistic regression was applied to test the association of
clinical diagnosis with SNP dosages under an additive model. Covariates
included sample grouping and principal components reflecting ancestry.
Detailed descriptions of the samples, data quality, genomic controls and
statistical analyses can be found in the original GWAS.27,28
Replication analyses were performed in nine independent BPD or MDD
samples that included 9920 patients and 13 973 controls, and no overlap
was found with the discovery samples. Detailed information on individual
samples—including diagnostic assessment, genotyping and quality control
—are shown in the Supplementary Data and Supplementary Table 1. Most
of these replication samples were previously reported in earlier large-scale
collaborative studies where they were found to be effective in detecting
genetic risk variants for BPD.10,22,29 Each of the original sample subjects
were recruited under relevant ethical and legal guidelines for their
respective areas, and all provided written informed consents prior to their
inclusion in the earlier studies. In brief, the origin and sizes of the
replication samples are as follows: (1) Sweden (1415 BPD cases and 1271
controls);29 (2) Romania (461 BPD cases and 329 controls);30 (3) Germany II
(181 BPD cases and 527 controls);14,29 (4) Australia (330 BPD cases and
1811 controls);14,22 (5) USA (58 BPD cases and 145 controls); (6) China-I
(198 BPD cases and 135 controls); (7) PsyCoLaus (1585 MDD cases and
2362 controls);15,29 (8) China-II (5303 MDD cases and 5337 controls);31 (9)
The Netherlands (389 MDD cases and 2056 controls).32
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SNP selection, genotyping and statistical analysis
For genotyping in our replication samples, we mainly used the Illumina
(San Diego, CA, USA) and Affymetrix platforms (details are shown in
Supplementary Data), and the genotyping yield was at least 99% in cases
and control subjects of all groups. During statistical analysis, for initial
screening in the discovery BPD and MDD samples, the statistics data from
a total of 559 SNPs covering 2.0 Mb in 13q21.1 region were obtained from
both GWAS samples. We utilized PLINK v1.07 to perform the meta-analysis
of the 559 SNPs in two samples. We used odds ratio (OR) and standard
error (SE) to estimate heterogeneity between individual samples and to
calculate the pooled OR and 95% confidence interval (CI) in the combined
samples. To combine the results from individual sample, we calculated the
heterogeneity between each samples using the Cochran’s (Q) χ2-test,
which is a weighted sum of the squares of the deviations of individual OR
estimates from the overall estimate. In the absence of heterogeneity
among individual studies, we used a fixed-effect model to combine the
sample and to calculate the pooled OR and the corresponding 95% CIs;
otherwise, a random-effect model was applied. The meta-analysis was
performed using the classical inverse variance weighted methods. These
regional association results of 559 SNPs were plotted using LocusZoom
(http://locuszoom.sph.umich.edu/locuszoom/).33 During the replication
analysis and all combined analysis on rs9537793, ‘metafor’ package in R
(http://www.R-project.org) was used to perform the meta-analysis using
appropriate genetic model. We used a forest plot to graphically present
the pooled ORs and the 95% CIs of rs9537793. Each study was represented
by a square in the plot, and the weight of each study was also shown. As
described in a previous GWAS meta-analysis,12 P-values for replication
samples are reported as one-tailed tests and P-values for all combined
samples are shown as two-tailed tests. P-value o8.94 × 10− 5 was set as
the statistical significance level in the discovery and combined samples; in
the replication sample, P-value o0.05 was considered significant.
Cognitive index
We used educational attainment as a ‘proxy phenotype’ for cognitive
function. Although it’s not a direct cognitive measure, educational
attainment is correlated with cognitive ability (r~0.5) and some
personality traits related to persistence and self-discipline.34 Educational
attainment is strongly associated with social outcomes, and there is a well-
documented health-education gradient. Estimates suggest that around
40% of the variance in educational attainment is explained by genetic
factors.34 The harmonized measurements of educational attainment were
coded by study-specific measures using the International Standard
Classification of Education (1997) scale,35 and included a binary variable
for college completion (named ‘College’, that is, whether college degree
was completed) and a quantitative variable defined as an individual’s years
of schooling (named ‘EduYears’, that is, number of years of schooling
completed). College may be more comparable across countries, whereas
EduYears contains more information about individual differences within
countries. Recently, a GWAS on these ‘educational attainment’ phenotypes
has been performed in 101 069 European individuals,34 and we utilized the
statistical results from their GWAS as our first-step analysis. Briefly,
educational attainment was measured at an age at which participants
were very likely to have completed their education (more than 95% of the
sample was at least 30). On average, participants have 13.3 years of
schooling, and 23.1% have a college degree. In the second-step analysis,36
we used a sample which included increasing number of subjects
(n=293 723) and has partial overlap with the first-step sample; in this
sample, only ‘EduYears’ phenotype was assessed, with the same standard
of measurement with the first-step analysis. Detailed information on the
samples, genotyping methods and statistical analyses can be found in the
original GWAS report.34,36
Personality traits measurement
Personality can be deemed as a set of characteristics that influence
people’s thoughts, feelings and behavior across a variety of settings. Over
the last century, scientific consensus has converged on a taxonomic model
of personality traits based on five higher-order dimensions of neuroticism,
extraversion, openness to experience, agreeableness and conscientious-
ness, known as the five-factor model.37 Neuroticism refers to the tendency
to experience diverse and relatively more intense negative emotions, and
is commonly defined as emotional instability; it involves the experience of
negative emotions such as anxiety, depression, hostility and the
vulnerability to stress. Neuroticism is a pervasive risk factor for different
psychiatric conditions including mood disorders and personality disorders,
and is also associated with entail emotional dysregulation.38,39
In 2015, the Genetics of Personality Consortium (GPC) conducted GWAS
on neuroticism40 in 63 661 individuals from Europe, United States and
Australia. We obtained the statistical results of PCDH17 risk SNP from this
GWAS as our discovery analysis.40 In brief to their GWAS, neuroticism
scores were harmonized across all 29 discovery cohorts by item response
theory analysis and statistics were performed against SNPs using additive
linear regression, with sex, age and principal components as covariates.
Later in 2016, Okbay et al.41 performed an expanded analysis (n=170 911)
by pooling summary statistics from the published study by the GPC40
(n=63 661) with results from a new analysis of UK Biobank data42 (UKB,
n= 107 245). In the UKB cohort, the measure was the respondent’s score
on a 12-item version of the Eysenck Personality Inventory Neuroticism.
Subcortical structure testing
Subcortical brain regions form circuits with cortical areas to learning,
memory43 and motivation,44 and altered circuits can lead to abnormal
behavior and disease.45 To investigate how common genetic variants
affect the structure of these brain regions, ENIGMA2 consortium
conducted GWASs on the volumes of several subcortical regions derived
from magnetic resonance images (MRI).46
We focused on two phenotypes (amygdala volume and hippocampal
volume) closely relevant to risk of mood disorders, and obtained the
statistical results from the ENIGMA2 GWAS discovery sample.46 In short, the
discovery sample includes 13 171 European subjects, the subcortical brain
measures (amygdala and hippocampus) were delineated in the brain using
well-validated, freely available brain segmentation software packages:
FIRST, part of the FMRIB Software Library (FSL), or FreeSurfer. The
standardized protocols for image analysis and quality assurance are
openly available online (http://enigma.ini.usc.edu/protocols/imaging-proto
cols/). For each SNP, the additive dosage value was regressed against the
trait of interest separately using a multiple linear regression framework
controlling for age, age,2 sex, four MDS components, ICV and diagnosis
(when applicable). For studies with data collected from several centers or
scanners, dummy-coded covariates were also included in the model.
Detailed information on the samples, imaging procedures and genotyping
methods can be found in the original GWAS.46
Functional MRI analysis
Imaging Subjects. Functional magnetic resonance images were obtained
from healthy German participants (N= 297) of European ancestry, as part
of a tricentric study on the neurogenetic mechanisms of psychiatric
disease (the MooDS cohort).47–49 The subjects were recruited from the
communities in Mannheim, Bonn and Berlin (mean age 33.77 ± 9.81 years,
134 males and 163 females). Exclusion criteria included a lifetime history of
significant general medical, psychiatric or neurological illness, prior drug or
alcohol abuse, head trauma, and the presence of a first-degree relative
with mental illness. This particular experiment was approved by the ethics
committees of the Universities of Bonn, Heidelberg and Berlin. All subjects
provided written informed consent to participate in the study.
Genotyping. rs9537793 genotyping was performed using Illumina Human
610-Quad and Illumina Human 660 W-Quad arrays (Illumina). The allele
frequencies for the SNPs were in the Hardy–Weinberg equilibrium (77 AA,
146 AG, 74 GG, P= 0.77). Age, handedness, sex, site and level of education
did not significantly differ between genotype groups (see Supplementary
Table 2 for characteristics of the matched sample).
Emotional Face-matching Task. During functional MRI (fMRI) scanning,
participants completed an emotional face-matching task. The face-
matching task is an implicit emotion processing task which has previously
been shown to robustly engage the amygdala.50,51 This task includes two
conditions: an emotional condition (matching faces) and a control
condition (matching shapes). In the emotional condition, subjects view
trios of faces with fearful or angry expressions and are asked to match the
two corresponding stimuli illustrating the same individual. In the control
condition, the participants view trios of simple geometric shapes (circles,
vertical and horizontal ellipses) and are asked to match the two
corresponding geometric shapes. The task is presented in eight blocks
of six trials (30 s) with alternating epochs of face- and shape-matching
conditions (task duration: 4.3 min or 130 whole-brain scans).
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Imaging parameters. Blood oxygenation level-dependent fMRI was
performed using three identical scanners (Siemens Trio 3 T; Siemens
Medical Solutions, Erlangen, Germany) at the Central Institute of Mental
Health Mannheim, University of Bonn and the Universitätsmedizin Charité,
Berlin. Data were acquired with gradient-recalled echo-planar imaging
(GRE-EPI) sequences with the following parameters: TR 2000 ms, TE 30 ms,
28 oblique slices (descending acquisition) per volume, 4 mm slice
thickness, 1 mm slice distance, 80° flip angle, 192 mm FOV, and 64 × 64
matrix. Quality assurance measures were conducted on every measure-
ment day at all sites according to a multicenter quality assurance protocol
revealing stable signals over time.
Functional Imaging Processing. fMRI images were processed using
Statistical Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/spm/).
The procedures followed our previously published studies with the same
task.52,53 In brief, the preprocessing included realignment, slice timing
correction, normalization to the Montreal Neurological Institute (MNI)
space with voxel size 3 × 3× 3 mm3, and spatial smoothing with a 9 mm
full-width at half-maximum (FWHM) Gaussian kernel. The preprocessed
images were then analyzed at two levels. At the first level, images for each
individual were analyzed using general linear models (GLM), where the
boxcar vectors for task conditions (convolved with the standard SPM
hemodynamic response function) were included as regressors of interest
and the six head motion parameters from the realignment step were
included as regressors of no interest. The data were high-pass filtered
(cutoff, 128 s) and individual maps for the ‘face-matching4shape-
matching’ contrast were computed. The contrast images were then used
for a second-level random effects analysis. To test for genetic association,
these contrast images were analyzed using the multiple regression model
including the three allelic groups (labelled as 0,1,2) as variable of interest
and age, sex and scanner site as the nuisance covariates. Significance was
measured at Po0.05 family-wise error corrected across an a priori defined
anatomical mask of the bilateral amygdala from the Automated
Anatomical Labeling atlas.54 To probe more precisely which subregion
the peak voxel was located, we further extracted three amygdala
subdivisions (superficial, latero-basal and centro-medial complex) from
the Anatomy toolbox55,56 and corrected the peak voxel across the three
subregional masks. The corrected P-values for each of the masks were
reported.
Healthy subjects for expression quantitative trait loci analysis
To identify the impact of risk SNPs on mRNA expression, we utilized a well-
characterized gene expression database BrainCloud (http://braincloud.
jhmi.edu/).57 The data in BrainCloud is aimed at increasing our under-
standing of the regulation of gene expression in the human brain and will
be of value to others pursuing functional follow-up of disease-associated
variants. The BrainCloud is comprised of 261 postmortem dorsolateral
prefrontal cortex of non-psychiatric normal individuals, including 113
Caucasian subjects and 148 African American individuals across the
lifespan. We used 224 postnatal individuals (110 Caucasians and 114
African Americans) from BrainCloud which contains the genotype data.
The raw genotype data were obtained from BrainCloud; expression data
and demographic information such as RNA integrity number, race, sex, and
age were also obtained. The prenatal subjects were removed from the
expression quantitative trait loci (eQTL) analysis since PCDH17 mRNA
expression is differentially expressed in fetal subjects compared with
postnatal subjects. The statistical analysis was conducted using linear
regression, with RNA integrity number, sex, race and age as covariates.
RNA-seq data processing in SMRI data set for diagnostic analysis
We downloaded raw RNA-sequencing reads from the SMRI data set (http://
sncid.stanleyresearch.org/) in the FASTQ file format. The RNA-seq data
were from frontal cortex (15 BPD, 15 MDD and 15 healthy controls)
generated by SMRI neuropathology collection. Reads after adaptors and
low quality filtering using btrim6458 were aligned to human reference
genome (hg38, http://asia.ensembl.org/index.html) through Tophat2
v2.0.14 (ref. 59) with mismatches, gap length as well as edit distance all
no more than 3 bases. Cufflinks v2.2.1 (ref. 60) was then applied to call new
transcripts and quantify both the new and old ones with default
parameters. For replicate samples, accepted hits bam files from Tophat2
alignment were merged by Samtools v0.1.18 (ref. 61) and the merged files
were utilized for the following Cufflinks quantification. Only reads uniquely
mapped to genes were used to calculate the gene expression level. To
quantify mRNA expression, FPKM (Fragments per Kilobase per Million
mapped reads) was calculated to measure gene-level expression according
to the formula: FPKM= R× 103/L× 106/N; where F is the number of
fragments mapping to the gene annotation, L is the length of the gene
structure in nucleotides, and N is the total number of sequence reads
mapped to the genome of chromosome.
Statistical analyses of mRNA expression associated with diagnosis were
conducted in R 3.0.1 using linear regression, covaring for RNA integrity
number, sex, age, race, duration of illness, brain pH, post-mortem interval,
suicide status and batch number in each sample. All reported two-sided P-
value s were calculated from t statistics computed from the log fold
change and its standard error from each multiple regression model, and
therefore represent covariate-adjusted P-values.
Pluripotent stem cell analysis
The expression analysis of PCDH17 in iPSCs and neurons derived from BPD
patients and healthy controls has been described in a previous study.62 In
brief, subjects contributing a skin sample were from a psychiatric clinic in a
mid-western college city, Caucasian, and were diagnosed with Bipolar I
Disorder, or healthy unaffected controls were ascertained through
advertising on the University of Michigan Clinical Studies website. To
characterize the iPSC and to determine whether there were differences in
their gene expression profiles with neuronal differentiation, total RNA was
isolated from six individual iPSC cell lines (3 BPD patients and 3 controls)
before and following 8 weeks of neuronal differentiation using the TRIzol
reagent (Invitrogen, Grand Island, NY, USA). The RNAs were amplified and
hybridized to GeneChip U133 Plus 2.0 microarrays (Affymetrix, Santa Clara,
CA, USA). Only complete sets of iPSC (three BPD patients and three
controls) and neurons (same three BPD patients and same three control
cell lines from six individuals) were analyzed to minimize stochastic
changes due to culture conditions. Detailed protocols about fibroblast
derivation, iPSC derivation and neuronal differentiation were described
previously.62
Plasmid constructs and reagents
The pCMV (Agilent Technologies, Santa Clara, CA, USA) encoding human
PCDH17 with a C terminus Myc-tag and pEGFP vector were used. The
integrity of constructs was verified by sequencing. The following anti-
bodies were used: GFP rabbit polyclonal (MBL) and Myc mouse
monoclonal (MBL).
Cortical neuronal cultures and transfection
Dissociated cortical neurons were prepared from cerebral cortex of C57BL/
6J mice embryonic (E16.5). In brief, cortices were dissected, trypsinized and
gently minced. Neurons were seeded to a density of 1 × 106 viable cells/
35 mm glass bottom dishes previously coated with poly-D-lysine
(1 mg ml− l) for at least 12 h at 37 °C. Cultures were maintained at 37 °C
with 5% CO2, supplemented with Neurobasal medium with 2% B27
(Invitrogen), penicillin/streptomycin (100 U ml− 1 and 100 μg ml− l, respec-
tively), 2.5 mM glutamine, and 5% fetal bovine serum. Cultures were
transfected with Lipofectamine 2000 (Invitrogen) at 17–18 days in vitro
(DIV) with EGFP plus mock plasmid or PCDH17-myc and maintained for
additional 1 day before imaging analysis.
Quantitative morphological analysis of dendritic spines
Transfected neurons were fixed in 4% paraformaldehyde with 4% sucrose
at 4 °C. Immunostaining with antibody to GFP was used to circumvent
potential unevenness of GFP diffusion in spines. For co-transfection
experiments, the neurons that clearly transfected with both GFP and
PCDH17-myc were captured as images. Transfected neurons were chosen
randomly and images were obtained using a TCS SP8 confocal microscope
(Leica Microsystems). The acquisition parameters were kept constant for all
scans in the same experiment. Deconvolution was performed and image
stacks (0.13 mm z series) were quick projected. The first or second
dendrites that were arborized from a neuron were subjected to
morphological analysis. Data analysis was carried out using ImageJ
software (NIH, MD, USA). Dendritic spine density was evaluated manually.
Individual spines on dendrites were traced and neck length and head
width of each spine was measured. To analyze spine morphology, at least
400 spines (from 16 neurons) were measured for each condition. On the
basis of morphology, spines were classified into the following categories:
(1) Thin, where the head width was o0.4 μm; (2) Mushroom, where the
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head width was 40.4 μm; and (3) Stubby, where the neck length was
o0.1 μm. Statistics were calculated in Prism v 6.07 (GraphPad Software,
San Diego, CA, USA). Spine density, neck length and spine width between
two groups were compared using two-sided student’s t-test. To compare
the proportion of different spine types between two groups, two-way
analysis of variance with Bonferroni post hoc test were used.
RESULTS
Overview of research strategy and experimental design
The sequence of hypothesis-driven experiments and tests leading
to converging evidence, from initial genetic screening to genetic
association with aspects of human cognition, personality, brain
structure and function and gene expression to confirmatory
experiments in tissue culture, is summarized in Figure 1.
Identification of rs9537793 on 13q21.1 associated with major
mood disorders
With the use of a BPD GWAS27 (10 410 cases and 10 700 controls)
and a MDD GWAS28 (9227 cases and 7383 controls) in European
populations (with no overlap in control subjects between the two
samples as stated in the original GWASs), we performed a meta-
analysis of 559 SNPs covering 2.0 Mb in the 13q21.1 region to test
whether any markers show region-wide significant associations.
One SNP, rs9537793, in the 3’ downstream of PCDH17 showed the
highest association with mood disorders among all the 559
variants (P-value = 3.30 × 10–5, OR = 1.067, Figure 2), followed by
rs9563520 (P-value = 8.72 × 10–5, OR = 1.086). These two SNPs
survived Bonferroni correction according to the number of
analyzed SNPs (n= 559), and are in low linkage disequilibrium
(LD) in European populations (r2= 0.21). Furthermore, none of the
other tested SNPs on 13q21.1 was in high LD with rs9537793 (all
r2o0.8), which was also supported by a higher density LD analysis
in 1000-Human-Genome European samples (Supplementary
Figure 1).
To further confirm the observed associations in the discovery
meta-analysis, we selected the top two SNPs (rs9537793 and
rs9563520) and conducted replication analyses in a large
collection of nine independent BPD and MDD case–control
samples. The final replication sample sets included 9920 patients
and 13 973 controls (Supplementary Table 1). Although the
sample sizes and ascertainment strategies differed from those of
the discovery meta-analysis, we also observed a significant
association of mood disorders with rs9537793 in these replication
samples (Prep = 1.70 × 10
–2, OR = 1.043). To increase the power of
statistical association, we conducted a meta-analysis on the
discovery and replication mood disorder samples using the R
package (metafor). This meta-analysis showed that rs9537793 was
significantly associated with major mood disorders in a total of
29 557 cases and 32 056 controls (Pmeta = 4.72 × 10
–6, OR = 1.058,
Figure 2), with no heterogeneity among individual samples
(Pheterogeneity = 0.560, I
2= 0). A separate analysis found that
rs9537793 was significantly associated with BPD
(PBPD = 1.40 × 10
–4, OR = 1.073) and MDD (PMDD= 6.08 × 10
–3, OR =
1.046), respectively. The results for each replication sample were
shown in Supplementary Table 3. Taken together, the association
analyses suggest that rs9537793 on 13q21.1 may confer genetic
risk towards major mood disorders. However, rs9563520 was not
significant in the replication samples (Supplementary Table 3), and
was therefore dropped from further analyses.
Effect of rs9537793 on cognition, personality, amygdala structure
and function
It has been reported that PCDH17 is expressed in amygdala
neurons,24 and we previously have shown that the gene is
enriched along corticobasal ganglia synapses in a zone-specific
manner during synaptogenesis.25 Here, with the use of GTEx
(Genotype-Tissue Expression project),63 a RNA-seq resource
comprising diverse human tissue samples, we showed that
PCDH17 is abundantly expressed in brain areas (Supplementary
Figure 2), such as amygdala, caudate, prefrontal cortex and
hippocampus etc. These brain regions subserve memory and
emotional processes, and have been frequently implicated in the
neuropathology of major mood disorders.3 We therefore hypothe-
sized that if the risk-associated SNPs affected the biology of these
brain regions, then deficits in cognition or other functions
mediated by these areas would also be associated with the risk
genotypes.
We first tested the effects of the risk SNP rs9537793 on
educational attainment, a ‘proxy phenotype’ of general cognitive
abilities (correlation r ~ 0.5).34 The first studied sample comprised
95 427 individuals for ‘College’ and 101 069 for “EduYears”.
Notably, rs9537793 was significantly associated with “EduYears”
(Beta = –0.011, P-value = 6.35 × 10–3, Supplementary Table 4), and
‘College’ (OR= 0.970, P-value = 1.04 × 10–3), with the risk allele
indicating lower educational levels.34 Furthermore, in another
overlapping sample with more subjects (n= 293 723) but only
focusing on the ‘EduYears’ phenotype,36 the association for
rs9537793 was substantially strengthened (Beta = –0.016,
P-value = 2.68 × 10–10).
Considering the abundant expression of PCDH17 in the
amygdala and caudate, recognized as key regions for emotional
processing,64–66 we then examined whether the risk SNP was also
associated with personality traits related to emotion. In the first
sample including 63 661 subjects,40 we found rs9537793 asso-
ciated with neuroticism (Beta = 0.014, P-value = 1.59 × 10–2,
Supplementary Table 5), an important emotional trait that was
significantly associated with mood disorders.38 Later, in an
overlapping cohort with larger sample size (n= 170 911),41 the
association between rs9537793 and neuroticism was strength-
ened (Beta = 0.010, P-value = 4.59 × 10–3). In these series of
analyses, the rs9537793 risk allele carriers tend to show increased
vulnerable personality traits compared to protective allele carries.
We also analyzed whether the risk SNP would relate to changes
in brain structure. Using region of interest analyses in MRI-based
morphometry of 13 171 individuals,46 we observed significant
volume decreases for risk allele carriers of rs9537793 in amygdala
(Beta = –5.92, P-value = 9.95 × 10–3, Supplementary Table 6) and
hippocampus (Beta = –9.08, P-value = 4.74 × 10–2), brain regions
responsible for emotional reactions and memory processing
which often show volumetric reductions in patients with mood
disorders.67
Significant associations of rs9537793 with emotional traits and
amygdala volume lead us to hypothesize this SNP may also be
associated with amygdala function underlying negative emotional
processing. Thus, we employed fMRI to test the effects of risk-
associated SNPs on amygdala activity during negative emotional
task, given the prior evidence that patients with mood disorders
have previously been shown to exhibit elevated amygdala activity
in response to negative emotional stimuli.68 There also is evidence
that individuals at increased genetic risk for bipolar disorder show
similar patterns of amygdala activity, suggesting that amygdala
hyperactivity may reflect a neural mechanism of genetic risk for
mood disorders.69 We hypothesized that healthy subjects who are
carriers of the risk-associated allele of PCDH17 would have
increased amygdala activity in response to negative emotional
stimuli (in an emotional face-matching task) compared with
carriers of the protective allele. With focus on amygdala activity,
we conducted a region of interest analysis on 297 subjects who
underwent this negative emotional face task during fMRI
scanning. This analysis revealed a significant linear effect of
rs9537793 on the activity of the right amygdala for the task
contrast (that is, emotional face-matching vs shape-matching;
T= 2.74, small-volume family-wise error corrected P-value = 0.046,
Figure 3). Homozygous risk allele carriers of rs9537793 (that is, GG)
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showed the highest amygdala activity, followed by heterozygotes
and protective allele (that is, A allele) homozygotes (Figure 3). This
association is also consistent with previous evidence of higher
amygdala activity in patients with mood disorders than healthy
controls in response to negative emotional stimuli.68 However,
rs9537793 did not show evidence of association with the left
amygdala activity. The laterality of this amygdala difference is in
agreement with the proposed general role of right hemisphere
brain regions in processing faces, as well as with recent reports
implicating a specific role for the right amygdala in processing
angry and fearful facial expressions.50,70 Additional analyses
indicated that the effect of rs9537793 on right amygdala activity
was independent of demographic characteristics (for example,
age, sex etc), and the genotype groups did not differ in
performance (accuracy and reaction time) on the emotional task,
indicating that general attentional, perceptual, and cognitive
phenomena did not contribute to the observed amygdala
differences.
Collectively, these data suggest that the PCDH17 rs9537793 not
only associates with clinical diagnosis of major mood disorders,
but also affects the specific intermediate phenotypes. These
results shed light on the potential neuronal mechanism of PCDH17
in the illnesses and neurodevelopment.
Risk genotypes in rs9537793 and diagnosis predict PCDH17 mRNA
expression
The associations of rs9537793 with major mood disorders and
with related intermediate phenotypes in multiple independent
samples lend statistical and neurological support to the involve-
ment of this genomic locus in the risk of illness. However, these
findings do not identify the underlying molecular mechanism.
Rs9537793 is in low LD with its surrounding SNPs (Supplementary
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Figure 1), and within 400 kb around rs9537793 there is only
PCDH17 gene, hence we focused on this gene in the following
analyses. In the existing human mRNA databases (Ensembl and
UCSC), there is only one known PCDH17 protein-coding transcript,
which is also further confirmed by junction-level analysis in brain
RNA-sequencing data from ENCODE and GTEx, which has been
described in our previous study.71 In brief, junctions are the RNA-
sequencing read counts that span at least two exons, and junction
reads between nonadjacent exons (exon-skipping junctions) are
indicators of alternative splicing. In PCDH17 such junctions are
quite rare. We thus investigated this PCDH17 canonical transcript
expression in brain tissues and its relationship to our evidence of
genetic risk. We utilized BrainCloud,57 a well-characterized gene
expression database which contains genetic variation and mRNA
data in human frontal cortex. Interestingly, the risk SNP rs9537793
was associated with PCDH17 mRNA expression in 224 healthy
postnatal individuals (P-value = 0.037, Figure 4a), with the risk
allele indicated higher mRNA levels.
The eQTL analyses showed a potential molecular mechanism for
genetic risk, but not association with illness per se. To gain further
insight into the potential pathophysiological roles of PCDH17, we
assessed the effects of diagnostic status on the expression
changes of PCDH17 mRNA. We analyzed the RNA-seq data of
frontal cortex in 15 BPD patients, 15 MDD cases and 15 healthy
controls. Although the PCDH17 is not increased in patients with
mood disorders (BPD and MDD combined) compared to healthy
controls (data not shown), it should be noted that gene expression
could easily be downstream changes from a variable genetic (or
environmental) influence, we therefore separated BPD and MDD
samples and compared PCDH17 expression in each diagnostic
group with healthy controls, respectively. Interestingly, we found
expression of PCDH17 to be significantly higher in individuals with
BPD compared to healthy controls (P-value = 0.023, Figure 4b),
which is consistent with the eQTL analysis of higher mRNA levels
in individuals carrying the risk alleles. In addition, in a previous
thalamic transcriptome study72 using the samples from SMRI
neuropathology collection (n= 15 each, schizophrenia/BPD/MDD/
controls), PCDH17 expression was again increased in patients with
BPD versus healthy controls (P-value = 0.047, Supplementary
Figure 3). However, PCDH17 expression did not differ between
MDD patients and healthy controls in these samples.
The involvement of PCDH17 in the development of BPD was
also supported by the expression analysis in BPD patients-derived
induced pluripotent stem cells (iPSCs) and neurons. It has become
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Figure 2. Genetic association of PCDH17 with risk for major mood disorders. A physical map of the region is given and depicts known genes
within the region. BPD, bipolar disorder; MDD, major depressive disorder.
Figure 3. Effect of the risk SNP rs9537793 on amygdala function. During
emotional face-matching task, carriers of the risk allele (G) of rs9537793
exhibited significantly increased allele-dosage-dependent activation in
the right amygdala (T=2.74, small-volume family-wise error (few)
corrected P-value =0.046). Number of subjects in each group: AA=77,
GA=146, GG=74. SNP, single-nucleotide polymorphism.
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apparent that iPSCs provide the opportunity to study the stepwise
differentiation of patient derived cells into neurons to identify
alterations in cell behavior and test novel therapeutic
approaches.73,74 Mood disorders are increasingly recognized as
neurodevelopmental disorders, and subtle alterations in gene
expression and pathways in early developmental events can
produce neurological consequences that only become apparent
much later in life.75 We therefore examined changes in PCDH17
expression during iPSCs derived from well-characterized patients
differentiate into neurons (BPD n= 3; Control n= 3) using data
from a previous study.62 Interestingly, PCDH17 expression tends to
show upregulation during this stage of neuronal differentiation in
both BPD patients (BPD iPSCs versus BPD neurons, P-value
o0.001) and control cell systems (control iPSCs versus control
neurons, P-value o0.001) (Figure 4c), suggesting this gene may
be involved in early brain development. Further, diagnostic
analysis found that expression of PCDH17 was higher in BPD
patients than healthy controls in both iPSCs (BPD iPSCs versus
control iPSCs, P-value o0.05) and neurons (BPD neurons versus
control neurons, P-value o0.05, Figure 4c).
Taken together, our data support the hypothesis that the
mechanism by which the disease-associated SNPs contribute to
risk for BPD and related phenotypes involves the regulation of
PCDH17 transcription and further suggest that overexpression of
this gene would result in the biological effects related to the
illness pathogenesis. The consistent case–control differences
observed for PCDH17 in BPD suggest that the molecular biology
of this gene involves broader elements of BPD pathogenesis than
just that of genetic risk. In contrast, the PCDH17 expression is not
altered in MDD patients, implying the link between PCDH17 and
MDD is primarily on its genetic risk level, and further studies are
necessary to validate this result.
Elevated PCDH17 expression results in decreased spine density
and abnormal spine morphology
Altered synaptic connectivity and plasticity have been repeatedly
reported in patients with mood disorders.76 Changes in dendritic
spine number and morphology are tightly coordinated with
synaptic function and plasticity,77,78 and loss of dendritic spines in
the brain has been seen in both individuals with BPD and
individuals with MDD,4 making it served as a common potential
substrate for the illnesses.
It is thus reasonable to hypothesize that PCDH17 would affect
the density or morphology of dendritic spines, where excitatory
synapses are placed.79 Accordingly, we investigated the onset of a
possible effect of PCDH17 on dendritic spine density and
morphology in vitro by confocal imaging analysis (Figure 5a). As
expected, overexpression of PCDH17 significantly decreased spine
density compared with the mock group (mock, 1.198 ± 0.078
spines per μm; overexpression of PCDH17, 0.907 ± 0.079 spines per
μm; P-value o0.05; Figure 5b). Intriguingly, increased expression
of PCDH17 also dramatically affected the morphology of dendritic
spines, that is, reduced the spines neck length compared with
mock group (mock, 0.862 ± 0.028 μm; overexpression of PCDH17,
0.679 ± 0.031 μm; P-value o0.001; Figure 5b). However, the spine
width did not differ between mock group and the PCDH17
overexpression group (mock, 0.481 ± 0.009 μm; overexpression of
PCDH17, 0.480 ± 0.012 μm; P-value 40.5; Figure 5b).
For a more detailed morphological analysis, dendritic spines
were categorized according to their shape (mushroom, stubby
and thin) using a highly validated classification method (see
Materials and methods section). As shown in Figure 5c, over-
expression of PCDH17 induced a significant reduction in the
proportion of mushroom spines (P-value o0.001) and a
concomitant significant increase in the proportion of stubby
spines (P-value o0.005), while the proportion of thin spines did
not differ between groups (P-value 40.5).
The above data suggests that elevated PCDH17 affects the
structure and density of dendritic spines, which will result in the
changes of synaptic transmission and plasticity. These
results further suggest a potential neuronal mechanism for the
neuropathology of PCDH17 in mood disorders as well as
dysfunctional memory, emotion and brain functions observed
in patients.
DISCUSSION
We report a genetic association with mood disorders within the
genomic region spanning PCDH17. To move beyond statistical
association with clinical diagnosis and to obtain convergent
evidence for association between PCDH17 and mood disorder
related biology, we have performed a series of convergent
experiments testing the effects of risk-associated SNPs on several
intermediate biological phenotypes. A consistent pattern of allelic
association, involving cognition, neuroticism as personality trait,
structural and functional imaging, was found in independent
samples and in expression of the PCDH17 gene in brain tissues.
The likelihood that the same risk-associated allele would predict
by chance variation in each of investigated phenotypes across
diverse samples and always in the direction of abnormality is
remote. To our knowledge, to date, the region of interest on
chromosome 13q21.1 has not been reported as a major locus in
the few GWAS of mood disorders.10,12–15 Those negative results
may reflect the fact that the sample size of individual GWAS is still
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small, as our meta-analysis combining the GWAS and independent
replication samples was necessary to detect associations of
PCDH17 SNPs. Conversely, the P-value s reported here would not
be significant if we corrected for all SNPs in the genome, and
further validations in larger samples are necessary. PCDH17
belongs to the protocadherin gene family, a subfamily of the
cadherin superfamily.80 The protein encoded by PCDH17 may
have a role in the establishment and function of specific cell− cell
connections in the brain. Notably, the identification of PCDH17 as
a susceptibility gene for major mood disorders is also consistent
with a prior report of another cadherin gene (FAT) as a potential
risk locus for BPD.81
Our results also provide support for the previous epidemiologic
evidence of genetic overlap between BPD and MDD. However, our
data do not explain why, among all those carrying risk alleles,
some develop BPD, others develop MDD and still others remain
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Figure 5. Overexpression of PCDH17 decreases spine density and results in abnormal spine morphology in cultured cortical neurons. Scale
bars represent 5 μm. (a) Cultured cortical neurons were transfected at DIV17-18 with EGFP plus mock plasmid or PCDH17-myc and maintained
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counted for each condition from four separate cultures. Error bars indicated s.e.m. *Po0.05, **Po0.005, ***Po0.001; Student's two-sided
t-test (b) and two-way analysis of variance post hoc Bonferroni test (c).
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apparently healthy. This phenomenon may reflect variation at a
larger number of genetic loci, only few of which have been
detected to date, environmental influences, and perhaps epige-
netic factors. The genetic architecture of major mood disorders
seems to be polygenic and/or highly heterogeneous, and the
genetic association findings so far seem to account for little of the
inherited risk for mood disorders. As robust findings accumulate
and sample sizes grow, the identified genes may highlight
pathways of etiologic relevance. In addition to major mood
disorders, PCDH17 is also implicated in a previous schizophrenia
study,82 in which PCDH17 was significantly increased in the brain
of schizophrenia patients. This is intriguing, as is usually the case,
genes are not specific for a psychiatric diagnosis, but are more like
a combinatorial building-block (Lego-like) structure underlies
psychiatric syndromes,83 and further studies are necessary to test
the contributions to PCDH17 to other neuropsychiatric disorders.
Exploring the potential effects of elevated PCDH17 levels on the
morphology and density of dendritic spines has noteworthy
implications for both normal brain function and the pathophysiol-
ogy of mood disorders. Synaptic dendritic spines are dynamic
structures that regulate neuronal responsiveness and plasticity,
and changes in dendritic spine number and morphology
accompany synapse formation, maintenance and elimination,
allowing the establishment and remodeling of connectivity within
neuronal circuits.84 Elimination of dendritic spines has been
observed in patients with BPD and MDD, as well as in cellular or
animal models by overexpressing/knockout risk genes for mood
disorders such as NRG3, DISC1, NRG1 and others.85–88 In this study,
we reported elevation in PCDH17 expression results in the loss of
dendritic spines, which might be able to explain the observed
association of PCDH17 with multiple brain functions and to
implicate a potential molecular and neuronal mechanism of
PCDH17 involvement in the risk for mood disorders. Since the
precise mechanisms detailing how PCDH17 affects the dendritic
spines and related synaptic functions remain unknown, further
work is therefore needed.
The discovery of PCDH17 in the risk of mood disorders may also
have therapeutic implications. Previous reports showed that
dendritic spines may serve as a common substrate for many
psychiatric disorders, particularly those that involve cognitive
deficits such as BPD and MDD. However, as spine modifications
are associated with cognitive function, spine deficits may be more
relevant for some cognitive symptoms or intermediate pheno-
types than others. Given the heterogeneity of these complex
disorders, some individuals may exhibit more marked spine
phenotypes, particularly those with more severe cognitive deficits.
Further studies of human neuropathology should strive to
understand the degree of correlation between severity of
cognitive deficits and dendritic spine dysmorphogenesis. The risk
genes that control spines provide a future direction for under-
standing how these genes disrupt synaptic function, neuronal
circuit organization and behavioral output in a disease-specific
manner. Thus, investigating the mechanisms can uncover future
candidate genes and identify the best molecular candidates for
therapeutic targeting. Indeed, many of the proteins in synapses
are enzymes that could be manipulated with designer small
molecules and drugs that target trophic and morphogenic
signaling pathways may prove to be more effective, as they
could alter cellular connectivity and induce fewer side effects. New
drugs may be designed to prevent the emergence of symptoms in
genetically susceptible individuals, delay the progression of
symptoms in the early stages of the disease, or mitigate symptoms
or promote functional recovery after the disease is fully
manifested. Specifically, drugs that target dendritic spine regula-
tion might aim to promote spine maturation and restore spine
stability, to fortify existing synapses and restore spine plasticity, or
to prevent synapse loss in mood disorders.
However, there are several limitations in the present study, and
we are cautious in the interpretation of the results. First, we
noticed that the association P-value s between rs9537793 and
major mood disorders did not achieve the conventional genome-
wide level of statistical significance (P= 5.00 × 10–8), and give the
herein observed OR (1.058), the results would not become
genome-wide significant until the sample size increases to
102 786 cases and 102 786 controls (have a power of 480%).
However, as mentioned in the previous aggregated analyses,15,16
BPD and MDD are polygenic disorders involving hundreds of
thousands alleles in it with each allele showing minor effect, and
there might be true findings among those markers only passing
nominal significance in the initial GWAS, but later were confirmed
in independent samples. Of note, we did not set up any in prior
hypothesis of choosing or dropping any SNPs 13q21.1, but
selected all the analyzed SNPs (n= 559) from previous GWAS data
sets27,28 in this genomic region without any bias. Although the
result did not achieve genome-wide significance, it does survive
multiple correction according to the number of tested SNPs
(n= 559) in this study (corrected P= 2.64 × 10–3). Second, we
realized that only two brain regions (amygdala and hippocampus)
were analyzed in the imaging analysis, further studies focusing on
more brain regions, such as prefrontal cortex and caudate, are
needed. Furthermore, we acknowledged that gene expression,
eQTL data, and primary neuronal cultures were performed using
tissues from prefrontal cortex, while structure and functional MRIs
mainly focused on amygdala region. Further analyses of gene
expression and primary neuronal cultures involving with amyg-
dala tissues (neurons) would strengthen the present study. Third,
we were aware that rs9537793 was associated with genetic risk of
both BPD and MDD, but diagnostic differential expression of
PCDH17 was only observed in patients with BPD. This incon-
sistency is not unexpected as gene expression could easily be
influenced by genetic, epigenetic and environmental factors. It is
thus possible that while PCDH17 confers risk for both BPD and
MDD in the genetic level, its expression in those patients are also
affected by varied factors associated with the specific pathogenic
processes of these two disorders, resulting in inconsistent results
between genetic analyses and gene expression profiles. However,
further studies are necessary to validate this contention.
In conclusion, we have identified and characterized a novel
gene with a potential genetic association with risk for mood
disorders. Individual carriers of mood disorders risk alleles show
shifts in cognitive performance, emotional stability (neuroticism),
amygdala structure and functions during negative emotion
processing in the same direction as mood disorder patients. The
mechanism of these risk associations seems to be related to the
genetic regulation of PCDH17 expression, which has critical
functions on the morphology and structure of dendritic spines.
Together, these results may provide new insights into the etiology
of mood disorders and a fresh direction for therapeutic
development.
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